When Tiana Nordstrom got off Ozempic, it was like a tap had been turned on in her head. Suddenly, all her thoughts the drug had suppressed about food and eating came flooding back. "It's relentless ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Tiana Nordstrom ...

The generic versions will give patients and healthcare providers access to “affordable alternatives" to brand name formats, says Canadian drug manufacturer, Apotex You can save this article by ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

1:24 Health Canada approves generic semaglutide for adults with type 2 diabetes Two generic versions of Ozempic and Wegovy are set to start arriving in Canadian pharmacies this week, which means ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Some Canadian ...

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

WASHINGTON, May 18 (Reuters) - U.S. President Donald Trump said on Monday that TrumpRx.gov, a government-backed website that lists discounted prescription drugs, will begin featuring generic medicines ...

President Trump announced the addition of 600 medicines to his online drugstore as he appeals to Americans concerned about high drug prices and affordability. By Rebecca Robbins President Trump said ...

India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Subscribe to read this story ad-free Get unlimited access to ...

Patent expiry across API, formulation, and device IP is expected to catalyze biosimilar competition, expanding access while compressing pricing across pharmaceutical and device value chains.